Crohns and ulcerative colitis Flashcards
Are there only two categories of IBD?
not necessarily, UC and CD are the main ones (polygenic) and like subcategories within them- and overlap between them.
But you also have early onset monogenic IBD.
what are typical presentations of CD?
persistent abdominal pain
non-bloody diarrhea
weight loss
perianal disease (fistulas and fissures)
what are typical presentations of UC?
short-lived cramps and abdominal pain
urgency to relieve themselves due to rectal inflammation.
blood and mucus in stools are seen in 96% of flares.
what sites of the Tract does CD affect?
anywhere from mouth to anus-
Often patchy inflammation of ileum, colon and ileo-colon area.
What sites of the tract does UC affect?
Large portion of the colon (large bowel).
How does inflammation and crypt presentation differ in CD and UC?
CD: inflammation can be deep and transmural
UC: inflammation is mucosal
CD: crypt is intact, but granulomas may be present.
U: crypts are distorted.
What complications can you see in CD and UC?
CD: ulcers, rashes and may overlap with ankylosing spondylitis.
UC: link with primary sclerosing cholangitis (PSC) and increased risk of bowel cancer.
what does PSC cause in UC?
affects the bile ducts, and leads to inflammation and strictures, increased risk of bowel cancer.
what is the age of onset like in both UC and CD?
younger preponderance (in UC may be due to protectiveness of smoking?)
What risks does smoking carry for UC and CD?
smoking increases risk of CD but decreases UC risk and progression.
What is most well-established therapy for monogenic and polygenic IBD?
HSCT can be for monogenic IBD
anti-TNFa (infliximab and adalimumab) for polygenic
What is the genetic concordance like for CD and UC patients in monozygotic twins?
CD: 40-45%
Uc-15-20%
What risk alleles affecting autophagy are thoguht to increase susceptibility to IBD in polygenic IBD?
NOD2 risk alleles, as well as ATG16C1 (and IRGM)
why might NOD2 risk alleles increase susceptibility to IBD?
NOD2 normally detects intracellular peptidoglycan and stimulates xenophagy, so increased microbial load in these patients if this is defective
(monogenic disease-causing IBD that affects autophagy is Nieman pick type C- although mainly has neurological defects)
There is alot of overlap in genetic risk alleles for UC and CD, which notable allele predisposes to both and each individually?
Those involved in the Th17 pathway: Il-23R (Il-12p40 and STAT3 (activation enhances Th17 survial)) predisposes to both.
NOD2 alleles only associated withCD.
HLA risk alleles only associated with UC.
What can affect microflora at young age, what can predispose children to later IBD?
Colonisation by skin or vaginal flora.
Multiple courses of antibiotics when young can alter the microbiome and increase IBD risk.
4 Indications that microbiome is important for disease and IBD?
Germ-free mice don’t develop the disease in mouse models for type 1 diabetes, EAE and IBD.
you can transfer colitis with the transfer of the microbiome from a mouse with colitis.
antibiotics can ameliorate disease.
Faecal stream diversion is effective.
what complications can arise because CD has a transmural inflammation?
Can cause ulcers, perforation and leakage in the peritoneum.
Fistulas.
2 aims of treatment?
To improve quality of life
Control inflammation which can increase risk of bowel cancer and CD progression.
what progression in CD can be seen if inflammation isn’t controlled?
fibrosis and narrowing of bowel leading to strictures and fistulas and surgery- repeats.
Although not a risk of strictures in UC what risk is there if inflammation not controlled?
risk of bowel cancer higher.
risk of sclerosing cholangitis (fibrosis and naroorwing of biliary ducts).
How can you maximise the benefit from inflixmab and adalimumab?
With earlier use of therapies- improved remission.
Reduce risk of antibodies against biologics with co-administration of immunodulators.
what is an anti-IL-6 monoclonal used in COVID treatment?
tocilizumab.
What drug is currently used to disrupt the IL-17 axis in IBD?
ustekinumab which non specifically targets p40 subunit of IL-23R and Il12R.
